
|Videos|April 26, 2022
Real-World Use of Targeted Agents in EGFR Exon 20–Positive NSCLC
Author(s)Zofia Piotrowska, MD, MHS
Practical advice regarding the selection and management of amivantamab or mobocertinib in patients diagnosed with EGFR exon 20–positive NSCLC.
Advertisement
Case: A 59-Year-Old Female with Lung Cancer
Initial presentation
- BC is a 59 y/o Asian female who presents to her physician complaining of shortness of breath, fatigue, and persistent right- sided neck pain.
- BC believes she is experiencing neck pain because of her new sleeping pillow.
- Since her last examination 6 months ago, BC has lost close to 10 lbs. BC has not changed her eating habits or style.
- PMH: Hypercholesterolemia (controlled)
- SMH: no history of smoking; drinks socially
- FH: she lives with her partner and 2 dogs; mother passed away from ovarian cancer 3 years ago.
- PE: LLL auscultation reveals decreased breath sounds visible bruising
Clinical workup
- Current Labs:
- CBC panel: Normal
- Liver function/Renal function: Normal
- CT Chest: LLL primary, mediastinal LNs; bone metastases
- Diagnosis: Stage IV adenocarcinoma
- MRI brain is negative for brain metastases
- CT scan of abdomen and pelvis shows additional bone metastases
- Weight: 120 lbs (54.5 kg)
- Biopsy of mediastinal lymph nodes shows stage 4 lung adenocarcinoma
- PD-L1 55%
Treatment
- NGS has been ordered and the results are pending.
- Patient initiated on a chemotherapy doublet.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways
1
FDA Approves Subcutaneous Daratumumab for Smoldering Multiple Myeloma
2
FDA Grants Orphan Drug Status to Novel CD33-Directed Immunotherapy for AML
3
Sacituzumab Govitecan Misses PFS in First-Line HR+/HER2– Metastatic Breast Cancer
4
Lurbinectedin and Tarlatamab in ES-SCLC
5








































